Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Global Health Network and the Family Larsson Rosenquist Foundation (FLRF) launch LactaHub: an open access knowledge platform featuring scientific and evidence-based information on breastfeeding and breastmilk for health professionals

Logos: TGHN and the Family Larsson Rosenquist Foundation

The Global Health Network and FLRF have created LactaHub to enable health professionals, decision-makers and researchers to be more effective in their daily work.

LactaHub is where scientific and evidence-based knowledge about breastfeeding and breastmilk will be brought together in a structured, practice-oriented manner. All content will be reviewed and verified for quality by an independent scientific editorial board, and made freely available.

LactaHub aims to become a thriving community of practice in the field of breastfeeding by:

  • Ensuring equal access to the best guidance and knowledge available, in one central location
  • Simplifying the search for objective information that has been independently verified
  • Opening new channels for knowledge transfer among health professionals – without physical or financial borders

Are you working in healthcare, policy or research with an interest in breastfeeding and the first 1,000 days? Learn more and please join the community

About The Global Health Network, of the University of Oxford

Faster and better research is critical to solving the world’s biggest health challenges. The Global Health Network enables researchers and organisations to share best practice and know-how with each other to drive progress, while empowering local health professionals undertaking research in the world’s most vulnerable settings. The Global Health Network facilitates sustainable health improvements through sharing of research methods, delivering training and supporting career development. The result is easier, faster, better research to help address the world's biggest health challenges.

About the Family Larsson Rosenquist Foundation

The Family Larsson-Rosenquist Foundation was established in 2013, born from the vision of a world in which every child is granted an optimum start in life through the benefits of breastmilk. Based in Frauenfeld, Switzerland, it is one of the world’s only philanthropic foundations dedicated entirely to supporting and promoting breastfeeding and breastmilk.

 

 

Similar stories

Indian authorities sign an MoU for a data and skill-sharing partnership between ICMR and IDDO

The Indian government’s Union Cabinet, chaired by Prime Minister Shri Narendra Modi, has approved a Memorandum of Understanding (MoU) between the Indian Council of Medical Research (ICMR) and the Infectious Diseases Data Observatory (IDDO), based at the University of Oxford.

The GRAM Project has moved

The Global Research on Antimicrobial Resistance (GRAM) Project has a new centre of operations at the University of Oxford, after moving this month from the Big Data Institute to the Centre for Tropical Medicine and Global Health, under the leadership of Dr. Benn Sartorius (PI) and Prof. Christiane Dolecek (co-PI).

Sharing expertise with scientific collaborators in India

The Indian Council for Medical Research (ICMR) National Institute of Malaria Research (NIMR) and IDDO collaborate on a joint capacity building venture to train young researchers across three infectious diseases: malaria, visceral leishmaniasis and lymphatic filariasis

Artemisinin combination therapy trials need longer follow-up to detect late treatment failures for Plasmodium falciparum malaria

WWARN researchers have been assessing the recommended minimum follow-up period in capturing polymerase chain reaction (PCR)-confirmed recrudescence following treatment with fixed-dose artemisinin combination therapies (ACTs) for patients with uncomplicated Plasmodium falciparum malaria.

Paxlovid to be investigated by the RECOVERY Trial as a potential treatment for patients hospitalised with COVID-19

The RECOVERY Trial begins testing the antiviral treatment Paxlovid. Paxlovid, an oral antiviral treatment developed by Pfizer, is a combination of nirmatrelvir and ritonavir. Nirmatrelvir inhibits an enzyme that is critical for the replication of the virus that causes COVID-19, whilst ritonavir increases the concentration of nirmatrelvir.

The RECOVERY Trial - two years on

One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of countless researchers, doctors, nurses, statisticians and supporting staff.